Vitamin D3 serum level in patients with multiple sclerosis

Authors

  • Ghasem Fattahzadeh Ardalani Department of Neurology, School of Medicine, Ardabil University of Medical Sciences, Ardabil, Iran
  • Alireza Khosravi Department of Neurology, School of Medicine, Zahedan University of Medical Sciences, Zahedan, Iran

DOI:

https://doi.org/10.18203/2349-3933.ijam20151016

Keywords:

Multiple sclerosis (MS), Vitamin D3, Serum level

Abstract

Background: The World Health Organization states that the prevalence of MS is increasing. Due to the growth in the number of people with MS, and because this disease involves the working youth community and is  a debilitating illness and also there is no exact treatment for it, thus, eliminating the risk factors of this disease through new and cost-effective methods is essential. It has been proven that vitamin D3 performs an active role in the immune system. The role of vitamin D on the immune system is to increase phagocytic monocytes and to reduce secretion of TNF-α, IL-12 and PGE2 by monocytes. Vitamin D3 serum Levels in MS patients have had conflicting results in different studies. The Purpose of this study was to compare serum levels of vitamin D3 in patients with MS and healthy subjects, and also to examine the relationship between vitamin D3 serum levels and the severity and the number of attacks in MS patients during a year.

Methods: In this case-control study, 60 patients with MS were selected for case group and 60 healthy people, matched to the case group in terms of sex and living conditions, were chosen as the control group. Serum samples were taken for laboratory examination of vitamin D3 serum levels. Then, the collected data was analyzed by SPSS.16.

Results: Of samples 25% were male, and the rest of them were female. The mean age of the control group was 20 ± 4 years and that of case group was 19.3 ± 2.8 years. The prevalence of deficiency and inadequate levels of vitamin D3 was higher in MS patients than healthy people in the control group. Deficiency of vitamin D3 was higher among women in both groups. In MS group, prevalence of inadequate levels of vitamin D3 was 35.6% among women, while it was 13.3% among men. But in the control group, prevalence of inadequate levels of vitamin D3 was higher among men (40% versus 13.3%). The incidence of recurrence was 13.3%, 11.1% and 11.1% among MS patients with normal levels of vitamin D3, MS patients with inadequate levels of vitamin D3, and MS patients with deficiency of Vitamin D3, respectively, but the difference between them was not statistically significant.

Conclusions: Results showed that the serum levels of vitamin D3 are low in Ardabil province and even lower among women; and particularly in MS patients compared to healthy people. There was no significant relation between the number of attacks per year and serum levels of vitamin D3. 

References

Pierrot-Deseilligny C. Clinical implications of a possible role of vitamin D in multiple sclerosis. J Neurol. 2009;256(9):1468-79.

Smolders J, Damoiseaux J, Menheere P, Hupperts R. Vitamin D as an immune modulator in multiple sclerosis, a review. J Neuroimmunol. 2008;194(1):7-17.

Shahbeigi S, Pakdaman H, Mirzaeei N, Nikravesh E. Study serum 25-hydroxyvitamin D levels in MS patients and compare with control group. Iran J Neurol. 2008;7(24):70-4.

Munger KL, Zhang S, O’reilly E, Hernan M, Olek M, Willett W, et al. Vitamin D intake and incidence of multiple sclerosis. Neurology. 2004;62(1):60-5.

Hejazi E, Amani R, Sharafaldin Zadeh N, Cheraghian B. Comparison of the dietary intake of vitamin D and serum 25-OH-vitamin D3 levels between multiple sclerosis patients and healthy subjects. Iran J Nutr Sci Food Technol. 2008;2(4):59-66.

Ponsonby A-L, McMichael A, Van Der Mei I. Ultraviolet radiation and autoimmune disease: insights from epidemiological research. Toxicology. 2002;181:71-8.

Soilu-Hänninen M, Airas L, Mononen I, Heikkilä A, Viljanen M, Hänninen A. 25-Hydroxyvitamin D levels in serum at the onset of multiple sclerosis. Multiple Sclerosis. 2005;11(3):266-71.

Ozgocmen S, Bulut S, Ilhan N, Gulkesen A, Ardicoglu O, Özkan Y. Vitamin D deficiency and reduced bone mineral density in multiple sclerosis: effect of ambulatory status and functional capacity. J Bone Mineral Metab. 2005;23(4):309-13.

Munger KL, Levin LI, Hollis BW, Howard NS, Ascherio A. Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA. 2006;296:2832-8.

Samantha MK, Melanie RU, Paul O, Reinhold V. Safety of vitamin D3 in adults with multiple sclerosis. Am J Clin Nutr. 2007;86(3):645-51.

Pierrot-Deseilligny C, Rivaud-Péchoux S, Clerson P, de Paz R, Souberbielle JC. Relationship between 25-OH-D serum level and relapse rate in multiple sclerosis patients before and after vitamin D supplementation. Ther Adv Neurol Disord. 2012 Jul;5(4):187-98.

Sedrani SH. Low 25-hydroxyvitamin D and normal serum calcium concentrations in Saudi Arabia: Riyadh region. Ann Nutr Metab. 1984;28(3):181-5.

Azizi F, Rais-Zadeh F, Mir Said Ghazi A. Vitamin D deficiency in a group of Tehran population. Res Med. 2000;4:291-303.

Downloads

Published

2017-01-22

Issue

Section

Original Research Articles